Remission of Refractory Membranous Nephropathy by Low-dose Rituximab: A Case Report

被引：1
|
作者：
Wang Xiao-Pei
Hu Zhang-Xue
Guo Dong-Yang
Tao Ye
机构：
[1] Chengdu
[2] Chengdu Military General Hospital
[3] Department of Nephrology
[4] Sichuan 610041
[5] Sichuan 610083
[6] Sichuan University
[7] West China Hospital
来源：
中华医学杂志英文版 | 2016年 / 129卷 / 07期
关键词：
Low-dose; Primary Membranous Nephropathy; Remission; Rituximab;
D O I：
暂无
中图分类号：
R692 [肾疾病];
学科分类号：
1002 ; 100210 ;
摘要：
Primary membranous nephropathy (PMN) is an antibody-mediated autoimmune glomerular disease. The incidence of PMN is 10/million populations/year and mostly adult patients present with nephrotic syndrom
引用
收藏
页码：871 / 873
页数：3
相关论文
共 50 条
  • [1] Remission of Refractory Membranous Nephropathy by Low-dose Rituximab: A Case Report
    Wang, Xiao-Pei
    Hu, Zhang-Xue
    Guo, Dong-Yang
    Tao, Ye
    CHINESE MEDICAL JOURNAL, 2016, 129 (07) : 871 - 873
  • [2] Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series
    Cortazar, Frank B.
    Leaf, David E.
    Owens, Charles T.
    Laliberte, Karen
    Pendergraft, William F., III
    Niles, John L.
    BMC NEPHROLOGY, 2017, 18 : 1 - 10
  • [3] Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series
    Frank B. Cortazar
    David E. Leaf
    Charles T. Owens
    Karen Laliberte
    William F. Pendergraft
    John L. Niles
    BMC Nephrology, 18
  • [4] A case report of remission of refractory membranous nephropathy progressing to stage 4 chronic kidney disease using low-dose rituximab A long-term follow-up
    Zhou, Xu-Jie
    Zhou, Fu-De
    Wang, Su-Xia
    Zhao, Ming-Hui
    MEDICINE, 2018, 97 (25)
  • [5] Low-dose rituximab is poorly effective in patients with primary membranous nephropathy
    Moroni, Gabriella
    Depetri, Federica
    Del Vecchio, Lucia
    Gallelli, Beniamina
    Raffiotta, Francesca
    Giglio, Elisa
    Brunini, Francesca
    D'Amico, Marco
    Longhi, Selena
    Radice, Antonella
    Messa, Piergiorgio
    Sinico, Renato Alberto
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 (10) : 1691 - 1696
  • [6] Successful treatment of patients with refractory idiopathic membranous nephropathy with low-dose Rituximab: A single-center experience
    Wang, Yao-Wei
    Wang, Xin-Hui
    Wang, Hong-Xia
    Yu, Ren-Huan
    WORLD JOURNAL OF CLINICAL CASES, 2023, 11 (03) : 566 - 575
  • [7] Low-dose Rituximab Monotherapy or in Combination with Tacrolimus Is Effective in Primary Membranous Nephropathy
    Pathak, Vivek
    Venkatesan, Madhav
    Regunathan-Shenk, Renu
    KIDNEY360, 2021, 2 (02): : 336 - 338
  • [8] Case Report: Complete Remission of C1q Nephropathy Treated With a Single Low-Dose Rituximab, a Reality or Coincidence?
    Ma, Rui
    Wu, Dengyan
    He, Zhiqin
    Chang, Qian
    Yang, Yonghong
    FRONTIERS IN PEDIATRICS, 2021, 8
  • [9] Long-term remission induced by low-dose rituximab for relapsed and refractory thrombotic thrombocytopenic purpura: A report of two cases
    Tong, Hong-Yan
    Ye, Li
    Ye, Xing-Nong
    Lu, De-Min
    Li, Ying
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2015, 10 (06) : 2295 - 2298
  • [10] Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy
    Teisseyre, Maxime
    Cremoni, Marion
    Boyer-Suavet, Sonia
    Crepin, Thomas
    Benzaken, Sylvia
    Zorzi, Kevin
    Esnault, Vincent
    Brglez, Vesna
    Seitz-Polski, Barbara
    FRONTIERS IN IMMUNOLOGY, 2021, 12
12345